Oral Drug Administration clinical trials at UCSF

1 research study open to eligible people

Showing trials for

  • FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

    open to eligible people ages 18 years and up

    The goal of this clinical trial is to study the safety and tolerability in all advanced solid tumors, including advanced urothelial carcinoma. The main question[s] it aims to answer are: - Is FX-909 safe and tolerable, as a monotherapy and in combination with Pembrolizumab - What is the right dose level for patients Participants will be asked to take FX-909 daily in tablet form, or FX-909 daily and Pembrolizumab every 3 weeks, and record any outcomes from taking the drug. Participants will also be asked to return for multiple site visits for various blood tests and to collect blood and tumor samples as well as have regular CT/MRI scans.

    San Francisco, California and other locations

Our lead scientists for Oral Drug Administration research studies include .

Last updated: